BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 9.6% during the fourth quarter, HoldingsChannel reports. The firm owned 92,228 shares of the medical equipment provider’s stock after purchasing an additional 8,061 shares during the period. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Hologic were worth $3,791,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HOLX. Oregon Public Employees Retirement Fund raised its position in Hologic by 3,960.1% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 1,222,766 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 1,192,649 shares in the last quarter. Lindbrook Capital LLC purchased a new stake in Hologic during the fourth quarter valued at about $36,000. Essex Savings Bank purchased a new stake in Hologic during the fourth quarter valued at about $37,000. Cerebellum GP LLC purchased a new stake in Hologic during the fourth quarter valued at about $43,000. Finally, Clean Yield Group purchased a new stake in Hologic during the fourth quarter valued at about $47,000. Institutional investors and hedge funds own 88.77% of the company’s stock.
Shares of NASDAQ:HOLX opened at $47.36 on Friday. Hologic, Inc. has a 12-month low of $35.10 and a 12-month high of $48.11. The stock has a market cap of $13.74 billion, a PE ratio of 21.24, a P/E/G ratio of 2.21 and a beta of 0.75. The company has a current ratio of 1.30, a quick ratio of 0.91 and a debt-to-equity ratio of 1.18.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, January 30th. The medical equipment provider reported $0.58 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.57 by $0.01. The firm had revenue of $830.70 million for the quarter, compared to analysts’ expectations of $823.22 million. Hologic had a positive return on equity of 25.59% and a negative net margin of 12.88%. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period last year, the firm earned $0.55 earnings per share. As a group, analysts anticipate that Hologic, Inc. will post 2.41 EPS for the current year.
A number of research firms have weighed in on HOLX. BidaskClub upgraded Hologic from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, November 21st. Piper Jaffray Companies raised their price target on Hologic to $49.00 and gave the company an “overweight” rating in a research report on Thursday, January 31st. BTIG Research reaffirmed a “buy” rating and set a $50.00 price objective on shares of Hologic in a research note on Thursday, January 31st. Zacks Investment Research cut Hologic from a “buy” rating to a “hold” rating in a research note on Thursday, February 21st. Finally, Morgan Stanley cut Hologic from an “equal weight” rating to an “underweight” rating and reduced their price objective for the company from $44.00 to $39.00 in a research note on Wednesday, January 2nd. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $44.52.
In related news, insider Benjamin Jordan Cohn sold 6,830 shares of the firm’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $46.70, for a total value of $318,961.00. Following the sale, the insider now directly owns 22,002 shares of the company’s stock, valued at $1,027,493.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Peter J. Valenti III sold 4,242 shares of the firm’s stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $47.38, for a total value of $200,985.96. The disclosure for this sale can be found here. 0.90% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: This report was first reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.thelincolnianonline.com/2019/03/15/british-columbia-investment-management-corp-grows-holdings-in-hologic-inc-holx.html.
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
Further Reading: Technical Analysis
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.